Japanese-based Eisai has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on lenvatinib mesylate in combination with everolimus, to treat adult patients with advanced renal cell carcinoma (RCC).

To be launched under the brand name Kisplyx, the anti-cancer agent lenvatinib mesylate can treat adult RCC patients after one prior vascular endothelial growth factor (VEGF) targeted therapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Lenvatinib is an orally administered, multiple receptor tyrosine kinase (RTK) inhibitor with an effective binding mode that particularly inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors and fibroblast growth factor (FGF) receptors.

"Advanced or metastatic RCC is currently difficult to treat with surgery, while the basic treatment method is molecular targeted drug therapy with five years of low survival rates."

The drug inhibits the additional proangiogenic and oncogenic pathway-related RTKs that includes the platelet-derived growth factor (PDGF) receptor PDGFRalpha, KIT, and RET, involved in tumour proliferation.

Advanced or metastatic RCC is currently difficult to treat with surgery, while the basic treatment method is molecular targeted drug therapy with five years of low survival rates.

See Also:

At present, Lenvatinib, under the product name Lenvima, has been introduced in several countries across the world that includes the US, Japan and different nations in Europe for treating patients with refractory thyroid cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In May this year, lenvatinib, in combination with everolimus, was approved by the US Food and Drug Administration (FAA) to treat patients with advanced RCC after one prior VEGF-targeted therapy.